Annexure I (Refer to Paragraph 6.1) Industry Policy-Government Decision Press Note dated 2nd Dec., 1973. Drugs & Pharmaceuticals - For FERA Drug Companies Following bulk drugs subject to a phased manufacture programme, and formulations based thereon with an overall ratio of bulk drug consumption (from own manufacture) to formulations from all sources of 1:4.

• Introductory • Part II - Objectives • Part III - Rational use of Drugs • Part IV - Quality Control • Part V - Pricing • Part VI - Licensing • Part VII - Duty Rationalisation • Part VIII - Co-ordination • Part IX - Review • Annexure - I • Annexure - II • Annexure - III

Rifampicin Verapamil Cephalexin Pantothenate Bacitracin Neomycin Cephaloridine Alkaloids of Ergot Thiopentone Propoxyphenazone Pyrantal Pamoate Norethisterone Oxethazine Pentazocine Norgestral Dipyridemol Tolnaftate Triprolidine Naproxen Nalidixic Acid Chlorpromazine Chlorpheniramine Betamethazone Dexamethazone Chloramphenicol Vitamic A Digoxin Dapsone Allopurinol Vitamin B12 Prednizolone Baralgan Ketone Isulin Primaquine Amodiaquine Succinyl Cholinechloride Clofazamine Thiabendazole Tetramisole Framycetin Cyclophosphamide Mepacrine Triamcinolone Phenuylephrine Oxytecin Vitamin P(Rutin) Prenylamine Lacate Thioridazine Phenolthiazine Penicillins Mianserin Hydrochloride Aminoglutethimid Cinnarizine Becampicillin Captopril Prazinuantel Tobramycin Timolol Cafazoline sodium Atenolol Nimustine Prithyldone Isosorbidemonoitrate Any new drug for which the company conducted clinical trials and obtained Drug Controller's approval. Polio Vaccine Measles Vaccine For non-FERA MRTP companies the existing definition would continue i.e. all bulk drugs and formulations subject to the ratio parameters applicable on the basis of turnover and subject to reservation for the public and small scale sectors.